|
1
|
Maccioni RB, Muñoz JP and Barbeito L: The
molecular bases of Alzheimer’s disease and other neurodegenerative
disorders. Arch Med Res. 32:367–381. 2001.
|
|
2
|
Yu MS, Leung SK, Lai SW, et al:
Neuroprotective effects of anti-aging oriental medicine Lycium
barbarum against β-amyloid peptide neurotoxicity. Exp Gerontol.
40:716–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh S, Kushwah AS, Singh R, Farswan M
and Kaur R: Current therapeutic strategy in Alzheimer’s disease.
Eur Rev Med Pharmacol Sci. 16:1651–1664. 2012.
|
|
4
|
Esmaeilzade B, Nobakht M, Joghataei MT, et
al: Delivery of epidermal neural crest stem cells (EPI-NCSC) to
hippocamp in Alzheimer’s disease rat model. Iran Biomed J. 16:1–9.
2012.PubMed/NCBI
|
|
5
|
Blurton-Jones M, Kitazawa M,
Martinez-Coria H, et al: Neural stem cells improve cognition via
BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci
USA. 106:13594–13599. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shi Y, Kirwan P, Smith J, MacLean G, Orkin
SH and Livesey FJ: A human stem cell model of early Alzheimer’s
disease pathology in Down syndrome. Sci Transl Med. 4:124–129.
2012.
|
|
7
|
Yahata N, Asai M, Kitaoka S, et al:
Anti-Aβ drug screening platform using human iPS cell-derived
neurons for the treatment of Alzheimer’s disease. PLoS One.
6:e257882011.
|
|
8
|
Kim H: Neuroprotective herbs for stroke
therapy in traditional eastern medicine. Neurol Res. 27:287–301.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pearl PL, Drillings IM and Conry JA: Herbs
in epilepsy: evidence for efficacy, toxicity, and interactions.
Semin Pediatr Neurol. 18:203–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schachter SC: Botanicals and herbs: a
traditional approach to treating epilepsy. Neurotherapeutics.
6:415–420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xue JF, Liu ZJ, Hu JF, Chen H, Zhang JT
and Chen NH: Ginsenoside Rb1 promotes neurotransmitter release by
modulating phosphorylation of synapsins through a cAMP-dependent
protein kinase pathway. Brain Res. 1106:91–98. 2006.PubMed/NCBI
|
|
12
|
Chuang CM, Hsieh CL, Lin HY and Lin JG:
Panax Notoginseng Burk attenuates impairment of learning and memory
functions and increases ED1, BDNF and beta-secretase immunoreactive
cells in chronic stage ischemia-reperfusion injured rats. Am J Chin
Med. 36:685–693. 2008. View Article : Google Scholar
|
|
13
|
Wei SG, Meng LQ and Huang RY: Effect of
Panax notoginseng saponins on serum neuronal specific enolase and
rehabilitation in patients with cerebral hemorrhage. Zhongguo Zhong
Xi Yi Jie He Za Zhi. 27:159–162. 2007.(In Chinese).
|
|
14
|
Zhong Z, Qu Z, Wang N, et al: Protective
effects of Panax notoginseng saponins against pathological lesion
of cholinergic neuron in rat model with Alzheimer’s disease. Zhong
Yao Cai. 28:119–122. 2005.(In Chinese).
|
|
15
|
Zhong Z, Qu Z, Bao Y, Wang N, Zhang F and
Zhang W: Effects of Panax notoginseng saponins in a rat model of
Alzheimer’s disease. Neural Regeneration Research. 3:37–40.
2008.PubMed/NCBI
|
|
16
|
Li X, Li M, Li Y, Quan Q and Wang J:
Cellular and molecular mechanisms underlying the action of
ginsenoside Rg1 against Alzheimer’s. Neural Regeneration Research.
7:2860–2866. 2012.PubMed/NCBI
|
|
17
|
Li X, Liu Y, Yuan HF and Quan QK: Effects
of gensenoside Rg1 on tau protein phosphorylation induced by
okadaic acid in rat brain slices. Zhong Xi Yi Jie He Xue Bao.
8:955–960. 2010.(In Chinese).
|
|
18
|
Wessa P: Spearman Rank Correlation
(v1-0.1) in Free Statistics Software (v1.1.23-r7). Office for
Research Development and Education. http://www.wessa.net/rwasp_spearman.wasp/uri.
Accessed June 27, 2013
|
|
19
|
Li L, Liu Z, Liu J, et al: Ginsenoside Rd
attenuates beta-amyloid-induced tau phosphorylation by altering the
functional balance of glycogen synthase kinase 3beta and protein
phosphatase 2A. Neurobiol Dis. 54:320–328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sontag JM, Nunbhakdi-Craig V, White CL
III, Halpain S and Sontag E: The protein phosphatase PP2A/Bα binds
to the microtubule-associated proteins Tau and MAP2 at a motif also
recognized by the kinase Fyn: Implications for tauopathies. J Biol
Chem. 287:14984–14993. 2012.
|
|
21
|
Nakamura K, Zhou XZ and Lu KP: Distinct
functions of cis and trans phosphorylated tau in Alzheimer’s
disease and their therapeutic implications. Curr Mol Med.
15–Nov;2012.(Epub ahead of print).
|
|
22
|
Rosenmann H, Meiner Z, Geylis V, Abramsky
O and Steinitz M: Detection of circulating antibodies against tau
protein in its unphosphorylated and in its neurofibrillary
tangles-related phosphorylated state in Alzheimer’s disease and
healthy subjects. Neurosci Lett. 410:90–93. 2006.PubMed/NCBI
|
|
23
|
Bancher C, Brunner C, Lassmann H, et al:
Accumulation of abnormally phosphorylated tau precedes the
formation of neurofibrillary tangles in Alzheimer’s disease. Brain
Res. 477:90–99. 1989.
|
|
24
|
Wang JZ, Grundke-Iqbal I and Iqbal K:
Kinases and phosphatases and tau sites involved in Alzheimer
neurofibrillary degeneration. Eur J Neurosci. 25:59–68. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoon SY, Choi JE, Kweon HS, et al: Okadaic
acid increases autophagosomes in rat neurons: Implications for
Alzheimer’s disease. J Neurosci Res. 86:3230–3239. 2008.PubMed/NCBI
|
|
26
|
Voss K, Koren J III and Dickey CA: The
earliest tau dysfunction in Alzheimer’s disease? Tau phosphorylated
at s422 as a toxic seed. Am J Pathol. 179:2148–2151. 2011.
|
|
27
|
Tota S, Goel R, Pachauri SD, et al: Effect
of angiotensin II on spatial memory, cerebral blood flow,
cholinergic neurotransmission, and brain derived neurotrophic
factor in rats. Psychopharmacology (Berl). 226:357–369. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scaini G, Comim CM, Oliveira GM, et al:
Chronic administration of branched-chain amino acids impairs
spatial memory and increases brain-derived neurotrophic factor in a
rat model. J Inherit Metab Dis. 30–Oct;2012.(Epub ahead of
print).
|
|
29
|
Wang Y, Zhang TY, Xin J, et al:
Differential involvement of brain-derived neurotrophic factor in
reconsolidation and consolidation of conditioned taste aversion
memory. PLoS One. 7:e499422012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nagahara AH, Merrill DA, Coppola G, et al:
Neuroprotective effects of brain-derived neurotrophic factor in
rodent and primate models of Alzheimer’s disease. Nat Med.
15:331–337. 2009.
|
|
31
|
Mufson EJ, Counts SE, Fahnestock M and
Ginsberg SD: Cholinotrophic molecular substrates of mild cognitive
impairment in the elderly. Curr Alzheimer Res. 4:340–350. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Laske C, Stellos K, Hoffmann N, et al:
Higher BDNF serum levels predict slower cognitive decline in
Alzheimer’s disease patients. Int J Neuropsychopharmacol.
14:399–404. 2011.PubMed/NCBI
|
|
33
|
Allen SJ, Watson JJ, Shoemark DK, Barua NU
and Patel NK: GDNF, NGF and BDNF as therapeutic options for
neurodegeneration. Pharmacol Ther. 138:155–175. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cardenas-Aguayo Mdel C, Kazim SF,
Grundke-Iqbal I and Iqbal K: Neurogenic and neurotrophic effects of
BDNF peptides in mouse hippocampal primary neuronal cell cultures.
PLoS One. 8:e535962013.PubMed/NCBI
|
